1
John E Starrett Jr, Muzammil M Mansuri, John C Martin, David R Tortolani, Joanne J Bronson: Prodrugs of phosphonates. Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Rega Stichting v z w, Max D Hensley, September 2, 1997: US05663159 (95 worldwide citation)

There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.


2
John E Starrett Jr, Muzammil M Mansuri, John C Martin, David R Tortolani, Joanne J Bronson: Prodrugs of phosphonates. Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Rega Stichting v z w, Max D Hensley, August 11, 1998: US05792756 (75 worldwide citation)

There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.


3

4
John E Starrett Jr, Muzammil M Mansuri, David R Tortolani: Retinoid-like compounds. Bristol Myers Squibb Company, William T Han, June 4, 1996: US05523457 (42 worldwide citation)

This invention relates to a retinoid mpound of formula I ##STR1## in which Y is --CO--NH--, --CR.sup.2 .dbd.CR.sup.3 --, --CO--O--, --O--CO--, --C(.dbd.S)--NH--, --C.tbd.C--, --O--CH.sub.2 --, --CH.sub.2 --O--, or --CH.sub.2 --CH.sub.2 --;


5
John E Starrett Jr, Kuo Long Yu, Muzammil M Mansuri, David R Tortolani, Peter R Reczek: Retinoid-like compounds. Bristol Myers Squibb Company, David M Morse, April 8, 1997: US05618839 (20 worldwide citation)

The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which


6
John E Starrett Jr, Kuo Long Yu, Muzammil M Mansuri, David R Tortolani, Peter R Reczek: Retinoid-like compounds. Bristol Myers Squibb Co, David M Morse, July 15, 1997: US05648385 (19 worldwide citation)

The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which


7
Wayne Vaccaro, Bingwei Vera Yang, Soong Hoon Kim, Tram Huynh, David R Tortolani, Kenneth J Leavitt, Wenying Li, Arthur M Doweyko, Xiao Tao Chen, Lidia Doweyko: Modulators of the glucocorticoid receptor and method. Bristol Myers Squibb Co, Burton Rodney, Laurelee A Duncan, February 7, 2006: US06995181 (12 worldwide citation)

Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structure where Z is CONR1R2 or CH2 ...


8
Wayne Vaccaro, Zhong Chen, Dharmpal S Dodd, Tram N Huynh, James Lin, Chunjian Liu, Christopher P Mussari, John S Tokarski, David R Tortolani, Stephen T Wrobleski, Shuqun Lin: Fused heterocyclic compounds useful as kinase modulators. Bristol Myers Squibb Company, Hong Liu, Laurelee A Duncan, May 25, 2010: US07723336 (10 worldwide citation)

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR3, and R1, R2, R3, X and Y are ...


9

10
Bingwei Vera Yang, Lidia M Doweyko, Wayne Vaccaro, Tram N Huynh, David R Tortolani, T G Murali Dhar: Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. Bristol Myers Squibb Company, Burton Rodney, Laurelee A Duncan, June 28, 2011: US07968577

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, ta ...



Click the thumbnails below to visualize the patent trend.